An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Refractory/Relapsed Multiple Myeloma (KarMMa-7)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Celgene Corporation
Start Date
January 3, 2022
End Date
December 31, 2026
Administered By
Duke Cancer Institute
Awarded By
Celgene Corporation
Start Date
January 3, 2022
End Date
December 31, 2026